Andrew Berens
Stock Analyst at Leerink Partners
(1.24)
# 3,545
Out of 4,945 analysts
94
Total ratings
45.24%
Success rate
-11.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Berens
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CELC Celcuity | Maintains: Outperform | $28 → $60 | $51.89 | +15.63% | 2 | Jul 28, 2025 | |
| COGT Cogent Biosciences | Maintains: Outperform | $16 → $18 | $11.73 | +53.45% | 5 | Jul 7, 2025 | |
| ARVN Arvinas | Downgrades: Market Perform | $10 → $9 | $7.08 | +27.12% | 6 | Jun 2, 2025 | |
| CMPX Compass Therapeutics | Upgrades: Outperform | $4 → $6 | $2.95 | +103.39% | 3 | Apr 2, 2025 | |
| AGIO Agios Pharmaceuticals | Downgrades: Market Perform | $60 → $56 | $36.72 | +52.51% | 11 | Sep 27, 2024 | |
| AZN AstraZeneca | Maintains: Outperform | $78 → $79 | $78.47 | +0.68% | 12 | Nov 14, 2022 | |
| CGEM Cullinan Therapeutics | Maintains: Outperform | $36 → $25 | $7.60 | +229.16% | 3 | May 13, 2022 | |
| AURA Aura Biosciences | Initiates: Outperform | $40 | $7.03 | +468.99% | 1 | Nov 23, 2021 | |
| CCCC C4 Therapeutics | Initiates: Outperform | $67 | $2.35 | +2,751.06% | 1 | Oct 14, 2021 | |
| NUVL Nuvalent | Maintains: Outperform | $125 → $140 | $76.80 | +82.29% | 2 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $2.67 | +1,135.96% | 1 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $10 → $25 | $14.30 | +74.89% | 10 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $74 → $96 | $119.02 | -19.34% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $78 | $86.16 | -9.47% | 12 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $48 | $66.94 | -28.29% | 5 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $28 | $10.56 | +165.15% | 3 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $27 | $1.48 | +1,724.32% | 7 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $20 | $4.35 | +359.77% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $6.92 | +261.27% | 1 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $8 | $12.65 | -36.76% | 7 | Jul 14, 2017 |
Celcuity
Jul 28, 2025
Maintains: Outperform
Price Target: $28 → $60
Current: $51.89
Upside: +15.63%
Cogent Biosciences
Jul 7, 2025
Maintains: Outperform
Price Target: $16 → $18
Current: $11.73
Upside: +53.45%
Arvinas
Jun 2, 2025
Downgrades: Market Perform
Price Target: $10 → $9
Current: $7.08
Upside: +27.12%
Compass Therapeutics
Apr 2, 2025
Upgrades: Outperform
Price Target: $4 → $6
Current: $2.95
Upside: +103.39%
Agios Pharmaceuticals
Sep 27, 2024
Downgrades: Market Perform
Price Target: $60 → $56
Current: $36.72
Upside: +52.51%
AstraZeneca
Nov 14, 2022
Maintains: Outperform
Price Target: $78 → $79
Current: $78.47
Upside: +0.68%
Cullinan Therapeutics
May 13, 2022
Maintains: Outperform
Price Target: $36 → $25
Current: $7.60
Upside: +229.16%
Aura Biosciences
Nov 23, 2021
Initiates: Outperform
Price Target: $40
Current: $7.03
Upside: +468.99%
C4 Therapeutics
Oct 14, 2021
Initiates: Outperform
Price Target: $67
Current: $2.35
Upside: +2,751.06%
Nuvalent
Jun 24, 2025
Maintains: Outperform
Price Target: $125 → $140
Current: $76.80
Upside: +82.29%
Dec 5, 2024
Initiates: Outperform
Price Target: $33
Current: $2.67
Upside: +1,135.96%
Nov 7, 2024
Upgrades: Outperform
Price Target: $10 → $25
Current: $14.30
Upside: +74.89%
Oct 21, 2024
Upgrades: Outperform
Price Target: $74 → $96
Current: $119.02
Upside: -19.34%
Dec 13, 2023
Upgrades: Outperform
Price Target: $78
Current: $86.16
Upside: -9.47%
Apr 17, 2023
Maintains: Outperform
Price Target: $35 → $48
Current: $66.94
Upside: -28.29%
Dec 13, 2022
Maintains: Outperform
Price Target: $37 → $28
Current: $10.56
Upside: +165.15%
Nov 10, 2022
Maintains: Outperform
Price Target: $42 → $27
Current: $1.48
Upside: +1,724.32%
Oct 14, 2021
Initiates: Market Perform
Price Target: $20
Current: $4.35
Upside: +359.77%
Sep 20, 2021
Initiates: Outperform
Price Target: $25
Current: $6.92
Upside: +261.27%
Jul 14, 2017
Maintains: Equal-Weight
Price Target: $16 → $8
Current: $12.65
Upside: -36.76%